Premium
Complete screening of the CFTR gene in Argentine cystic fibrosis patients
Author(s) -
Visich A,
Zielenski J,
Castaños C,
Diez G,
Grenoville M,
Segal E,
Barreiro C,
Tsui LC,
Chertkoff L
Publication year - 2002
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1034/j.1399-0004.2002.610307.x
Subject(s) - cystic fibrosis , heteroduplex , genetics , allele , biology , mutation , cystic fibrosis transmembrane conductance regulator , gene , coding region , multiplex ligation dependent probe amplification , δf508 , allele frequency , population , microbiology and biotechnology , multiplex polymerase chain reaction , exon , polymerase chain reaction , medicine , environmental health
In order to establish the nature and the distribution of mutations causing cystic fibrosis (CF) in 220 unrelated Argentine families, the present authors conducted an extensive molecular analysis of the CF transmembrane regulator (CFTR) gene. First, a direct mutation analysis of 13 common mutations was done, enabling the detection of 319 out of 440 CF alleles (72.52%). Then an exhaustive screening of the entire coding region and the adjacent sequences of the CFTR gene was performed in all patients carrying at least one unidentified CF allele using the multiplex heteroduplex analysis assay followed by direct DNA sequencing. Thirty‐nine different CF mutations, including five previously undescribed mutations (i.e. L6V, Y362X, 1353insT, 2594delGT and 2686insT) and two novel polymorphisms (i.e. 1170G/C and 3315A/C) were identified. As a result, the overall detection rate increased by up to 83.45%. Besides ΔF508, only five mutations showed frequencies higher than 1%. In addition, a total of 49% of the mutations were rare because they were found in only one CF family. This wide spectrum of CF mutations is in agreement with the heterogeneous ethnic origin of the Argentine population. The data obtained here may have important consequences for the development of adequate strategies for the molecular diagnosis of CF in Argentina.